Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

697
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
697
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

5.1K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.1K
Principles of Drug Action01:24

Principles of Drug Action

5.9K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
5.9K
Enzyme Inhibition01:30

Enzyme Inhibition

78.2K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.2K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

538
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
538

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

m<sup>6</sup>A modification suppresses innate anti-tumour immunity in colorectal cancer by limiting alu-derived dsRNA accumulation.

Nature communications·2026
Same author

Identifying novel prodromal symptoms of eclampsia: A two-country, case-control study.

PLoS medicine·2026
Same author

Hypoxia inducible factors regulate pneumovirus replication by enhancing innate immune sensing.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Single-cell analysis of signalling and transcriptional responses to type I interferons.

EMBO reports·2026
Same author

DNA methyltransferase inhibitors in oncology: clinical progress, limitations and future directions.

Epigenomics·2026
Same author

In vivo CRISPR screening identifies SAGA complex members as key regulators of hematopoiesis.

Nature communications·2026
Same journal

Horizontal transfer of mitochondria in cancer: The physiology reborn in disease?

Trends in cell biology·2026
Same journal

Spindle errors: A stress test for epithelial robustness.

Trends in cell biology·2026
Same journal

Multicellular ecosystems: Linking cellular diversity to tissue function and disease.

Trends in cell biology·2026
Same journal

Orchestrating the signaling-bias at the protease-activated receptor, PAR1.

Trends in cell biology·2026
Same journal

Crashing by design: Utilizing DNA damage for MCC differentiation.

Trends in cell biology·2026
Same journal

The value of a shared lab: Our insights.

Trends in cell biology·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

ADAR1: from basic mechanisms to inhibitors.

Jan Rehwinkel1, Parinaz Mehdipour2

  • 1Medical Research Council Translational Immune Discovery Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DS, UK.

Trends in Cell Biology
|July 19, 2024
PubMed
Summary
This summary is machine-generated.

Adenosine deaminase acting on RNA 1 (ADAR1) prevents self-RNA from triggering innate immunity. ADAR1 deficiency causes inflammation, but inhibiting ADAR1 may offer new cancer therapies.

Keywords:
ADAR1MDA5RNA editingZBP1innate immunitytype I interferon

More Related Videos

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies
04:17

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies

Published on: September 27, 2024

646
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.9K

Related Experiment Videos

Last Updated: Jun 20, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K
Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies
04:17

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies

Published on: September 27, 2024

646
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.9K

Area of Science:

  • Molecular Biology
  • Immunology
  • Genetics

Background:

  • Adenosine deaminase acting on RNA 1 (ADAR1) performs A-to-I editing on double-stranded RNA (dsRNA).
  • ADAR1 deficiency leads to spontaneous innate immune responses and inflammatory diseases in humans and mice.
  • Unedited RNAs in ADAR1-deficient cells activate RNA sensors like MDA5, PKR, OAS, and ZBP1.

Purpose of the Study:

  • To review recent discoveries on ADAR1's role in innate immunity.
  • To discuss the implications of ADAR1 function in human diseases.
  • To explore the potential of ADAR1 inhibitors in cancer therapy.

Main Methods:

  • Literature review of ADAR1's function and disease implications.
  • Analysis of RNA sensing pathways activated by unedited RNAs.
  • Discussion of therapeutic strategies targeting ADAR1.

Main Results:

  • ADAR1 editing of dsRNA, including repetitive elements, prevents immune activation.
  • ADAR1 deficiency results in type I interferon production via MDA5.
  • Tumors utilize ADAR1 for immune evasion.

Conclusions:

  • ADAR1 is crucial for distinguishing self from non-self RNA and maintaining immune homeostasis.
  • Dysregulation of ADAR1 contributes to inflammatory diseases and cancer progression.
  • Targeting ADAR1 presents a promising avenue for novel cancer treatments.